17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

28 10, 2022

miND spike-in

2023-03-10T10:13:11+01:00October 28th, 2022|microRNA, NGS, smallRNA|Comments Off on miND spike-in

TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving  absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins

2 03, 2022

miRNA NGS Discovery pipeline – miND

2023-03-10T10:13:34+01:00March 2nd, 2022|biomarkers, microRNA, NGS|Comments Off on miRNA NGS Discovery pipeline – miND

TAmiRNA present microRNA Next-Generation-Sequencing Discovery Assay (miND), a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. Eager to learn more - have a look at our two new publications! click here for more Information on the novel wet-lab small RNA-seq workflow and here for more insights into the bioinformatic pipeline

Go to Top